Men who have stable coronary artery disease who also take Viagra may live longer and have a lower risk of having a new heart attack than those who suffer from the disease, but not taking the erectile dysfunction drug, according to new findings. Study published in the Journal of the American College of Cardiology.
Researchers with the Karolinska Institute in Sweden compared the effects of various ED drugs in men with stable coronary artery disease. All participants had a heart attack, underwent balloon dilation (cardiac catheterization procedure), or underwent bypass surgery six months before starting ED treatment.
By collecting data on patient, drug, and death registration causes, the researchers looked at 16,500 men who had been treated with PDE5 inhibitors such as Viagra or Cialis, while only less than 2,000 participants received an injectable drug used to treat ED.
By the end, the researchers found that men treated with PDE5 inhibitors lived longer and had a lower risk of new heart attack, heart failure, balloon dilation and bypass surgery than those who received alprostedil.
Urinals may spread coronavirus, studies show
“The defense was dose-dependent, so the higher the dose of the PDE5 inhibitor, the lower the risk,” one of the findings reported.
“Potential problems are common in older men and now our study also shows that PDE5 inhibitors can protect against heart attack and prolonged life,” said Dr. A.S., an assistant professor in the Department of Medicine at the Karolinska Institute who led the study. Said Martin Holzman. In a statement.
Penis microbes will study in common and AG genital infections, find studies
The researchers speculated that the results could be because some ED drugs, such as Viagra, lower blood pressure, as high blood pressure is a risk factor for heart disease. That said, Holzman noted that the study is observable and requires further research on the subject.
“This suggests that there is a functional relationship, but the registry study cannot answer that question,” Holzman said in a statement. “It is possible that those receiving PDE5 inhibitors were healthier than those on alprostedil and therefore had a lower risk. To check whether it is a drug that reduces the risk, we will need to randomly assign patients to two groups who take PDE5 and That’s not the case. The results we have now are very good reason to be involved in such a study. “
